NEW YORK, NY / ACCESSWIRE / September 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Abiomed, Inc. (NASDAQGS:ABMD)
Lawsuit on behalf of: investors who purchased January 31, 2019 - July 31, 2019
Lead Plaintiff Deadline : October 7, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?prid=3581&wire=1
According to the filed complaint, during the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
International Flavors & Fragrances Inc. (NYSE:IFF)
Lawsuit on behalf of: investors who purchased May 7, 2018 - August 5, 2019
Lead Plaintiff Deadline : October 11, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/international-flavors-fragrances-inc-loss-form?prid=3581&wire=1
According to the filed complaint, during the class period, International Flavors & Fragrances Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom's financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Lawsuit on behalf of: investors who purchased September 6, 2017 - August 19, 2019
Lead Plaintiff Deadline : October 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?prid=3581&wire=1
According to the filed complaint, during the class period, Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/560196/CLASS-ACTION-UPDATE-for-ABMD-IFF-and-SRPT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders